Rockville, Maryland, has been a prominent center for the life sciences industry for over two decades, hosting a diverse range of biotech companies in Rockville MD that are developing new therapies, diagnostics, and treatments for various diseases. that are developing new therapies, diagnostics, and treatments for various diseases. The region’s proximity to major research institutions and regulatory agencies like the FDA makes it a strategic location for biotechnology innovation. Many biotechnology companies in Rockville MD focus on immunotherapy, gene therapy, molecular diagnostics, and pharmaceutical research. This blog highlights 30 Rockville biotech companies that are advancing healthcare through scientific research and medical advancements.
American Gene Technologies is a clinical-stage gene and cell therapy company specializing in genetic medicines to treat viral and oncological diseases. Their lead therapeutic, AGT103-T, is in Phase 1 clinical trials as a potential functional cure for HIV, with preliminary data showing promising immune response outcomes. The company also works on gene therapy solutions for liver cancer and phenylketonuria (PKU). As one of the leading biotech companies Rockville MD hosts, American Gene Technologies leverages advanced gene-editing techniques to develop lasting treatments.
MacroGenics focuses on developing monoclonal and bispecific antibodies for treating cancer and autoimmune disorders, with their approved drug MARGENZA (margetuximab) and multiple candidates in clinical trials. Their innovative approach to engineering antibodies allows for targeted therapy, reducing side effects while improving efficacy. With multiple candidates in clinical trials, MacroGenics is a well-established player among pharmaceutical companies Rockville MD.
MaxCyte is a global leader in cell-engineering technology, providing scalable electroporation platforms for cell therapy development. Their proprietary Flow Electroporation technology is widely used in drug discovery and cell-based therapies. This makes MaxCyte an integral part of the Rockville pharmaceutical companies network, supporting the development of next-generation treatments.
Meso Scale Discovery is a leader in biomarker analysis, offering high-sensitivity immunoassays that aid in disease research and drug development. Their technologies are widely used in preclinical and clinical research to evaluate biomarkers in diseases like cancer, neurodegeneration, and autoimmune disorders. As one of the top Rockville MD pharmaceutical companies, Meso Scale Discovery plays a crucial role in biomedical innovation.
NeoImmuneTech is dedicated to enhancing immunotherapy outcomes through its long-acting cytokine, NT-I7. This novel approach amplifies the body’s immune response against cancer and infectious diseases. The company is actively collaborating with pharmaceutical firms and academic institutions to further its research, securing its position as a key player in biotechnology companies in Rockville MD.
Polaris Genomics focuses on developing genomic biomarkers for mental health disorders, particularly post-traumatic stress disorder (PTSD). Their innovative research aims to improve early detection and personalized treatment strategies. The company’s work aligns with the broader mission of Rockville MD pharmaceutical companies, emphasizing precision medicine for mental health.
ReveraGen BioPharma specializes in developing steroidal and non-steroidal anti-inflammatory therapies for Duchenne muscular dystrophy (DMD). Their lead candidate, vamorolone, offers an alternative to traditional corticosteroids, providing treatment with fewer side effects. As a recognized name among pharmaceutical companies Rockville MD, ReveraGen BioPharma is advancing therapies for rare diseases.
RRD International provides regulatory and development consulting services to biotech firms, helping them navigate the complexities of clinical trials and FDA approvals. Their expertise makes them an essential partner for biotechnology companies in Rockville MD that are advancing new therapeutics from research to commercialization.
Sanaria is dedicated to eradicating malaria through its whole-parasite vaccine approach, with its lead candidate, PfSPZ, currently undergoing Phase 2 and Phase 3 trials in multiple regions including Africa and Southeast Asia. Their research has received global recognition, and their vaccine candidates are undergoing trials with promising results. As one of the specialized Rockville biotech companies, Sanaria’s efforts contribute to global infectious disease prevention.
Sensei Biotherapeutics is a clinical-stage immunotherapy company developing precision immuno-oncology treatments, with a focus on SNS-101, an anti-VISTA monoclonal antibody designed to enhance immune responses against tumors. Their lead product candidate, SNS-101, is designed to enhance immune responses against tumors. Their focus on immuno-oncology strengthens the presence of Rockville pharmaceutical companies in cancer research.
Sequella is a clinical-stage pharmaceutical company developing antibiotics to treat drug-resistant bacterial infections. The company's lead compound, sutezolid, is a next-generation oxazolidinone antibiotic that has demonstrated potential for treating tuberculosis (TB). Sequella has worked in collaboration with global health organizations to advance novel treatments addressing the growing problem of antimicrobial resistance. Their research is particularly relevant for Rockville MD pharmaceutical companies engaged in infectious disease therapeutics.
Shuttle Pharmaceuticals is focused on developing radiation sensitizers to improve cancer treatment. Their lead drug candidates are designed to enhance the effectiveness of radiation therapy, potentially reducing the required radiation dose and minimizing damage to surrounding healthy tissues. The company’s scientific team includes experienced oncologists and radiologists working to advance personalized radiation treatment regimens. This makes them a key contributor among Rockville pharmaceutical companies focused on oncology.
Sigmovir Biosystems specializes in developing animal models for infectious disease research, with a primary focus on respiratory syncytial virus (RSV). Their proprietary cotton rat model is widely used in vaccine and antiviral drug development. Pharmaceutical and biotech companies worldwide rely on Sigmovir’s research models to assess the efficacy of new therapies before clinical trials. Their expertise in preclinical research solidifies their role within biotechnology companies in Rockville MD supporting translational medicine.
Supernus Pharmaceuticals is a publicly traded company that focuses on developing and commercializing treatments for central nervous system (CNS) disorders. Their portfolio includes FDA-approved drugs for epilepsy, ADHD, and Parkinson’s disease, such as Oxtellar XR and Trokendi XR. The company continues to invest in new formulations and delivery systems to improve patient outcomes. With a strong commercial presence, Supernus is one of the leading pharmaceutical companies Rockville MD driving innovation in neuroscience.
SYNAPS Dx has developed the DISCERN™ test, one of the first laboratory diagnostics designed to provide early and accurate diagnosis of Alzheimer’s disease. The test differentiates Alzheimer’s from other forms of dementia using biomarkers identified in skin samples. Early detection enables better treatment planning and improved patient management. Their work in neurodegenerative diagnostics positions them among pioneering Rockville biotech companies working in personalized medicine.
TCR2 Therapeutics is developing T cell receptor (TCR) therapies for solid tumors. Their lead product, gavo-cel, is currently in clinical trials targeting mesothelin-expressing cancers such as ovarian, lung, and pancreatic cancer. Unlike conventional CAR-T therapies, TCR2's proprietary TRuC™ platform allows T cells to harness the full signaling power of the TCR complex, enhancing immune response. This differentiates TCR2 from other biotech companies Rockville MD working in cell-based cancer therapies.
Tetracore specializes in molecular diagnostics and biodefense solutions. They develop PCR-based assays for the rapid detection of infectious diseases and biological threat agents. Tetracore’s portable diagnostic platforms are used by government agencies, research labs, and healthcare facilities to detect pathogens such as anthrax, avian flu, and African swine fever. Their commitment to infectious disease preparedness makes them a critical player among Rockville pharmaceutical companies advancing rapid diagnostics.
Formerly known as Synthetic Biologics, Theriva Biologics focuses on the development of oncolytic viruses for cancer therapy. Their lead candidate, SYN-004 (ribaxamase), is designed to protect the gut microbiome from antibiotic damage, thereby preventing opportunistic infections like Clostridioides difficile. Additionally, their work in viral-based therapeutics for cancer makes them a notable contributor to biotechnology companies in Rockville MD focused on microbiome research and immunotherapy.
Trophogen develops recombinant human hormones and growth factors for fertility treatments and endocrinology applications. Their proprietary receptor-binding technology enhances the potency and bioavailability of traditional hormone therapies, making them more effective for patients undergoing assisted reproductive treatments. Trophogen's research aligns with the broader goals of Rockville MD pharmaceutical companies improving reproductive health and hormone-based therapies.
The Wellstat Group is a privately held collection of biotechnology and pharmaceutical companies focusing on metabolic and neurological disorders. One of its subsidiaries, Wellstat Therapeutics, developed Vistogard® (uridine triacetate), an FDA-approved antidote for severe 5-fluorouracil (5-FU) toxicity. Their commitment to developing life-saving treatments for rare and underserved conditions positions them as a leader within Rockville biotech companies investing in precision medicine.
REGENXBIO is a clinical-stage gene therapy company developing one-time treatments for severe genetic diseases and chronic conditions. Their NAV Technology Platform is used in multiple investigational and approved gene therapies, including treatments for retinal diseases and neuromuscular disorders. Their lead candidate, RGX-314, is in Phase 3 trials for wet age-related macular degeneration (wet AMD) and diabetic retinopathy, positioning them among leading biotech companies in Rockville MD focused on gene therapy.
Arcellx is pioneering next-generation cell therapies for cancer and autoimmune diseases. Their lead asset, CART-ddBCMA, is in late-stage trials for relapsed or refractory multiple myeloma. Their proprietary ARC-SparX technology enables greater control over CAR-T cell therapies, aiming to improve efficacy and reduce toxicity. Their advancements place them among Rockville pharmaceutical companies leading the future of oncology treatment.
Aurinia Pharmaceuticals is a commercial-stage biotech company specializing in immunology and autoimmune diseases. Their FDA-approved drug, Lupkynis (voclosporin), is the first oral therapy for lupus nephritis, a serious complication of lupus. The company continues to develop treatments for fibrotic and autoimmune conditions, solidifying its role among Rockville MD pharmaceutical companies working in immunology.
BioFactura is an emerging biopharmaceutical company specializing in the development and manufacturing of biosimilars, biodefense countermeasures, and novel biologics. Their proprietary StableFast™ Biomanufacturing Platform enables efficient and cost-effective production of biologics, helping Rockville pharmaceutical companies accelerate drug development while maintaining high-quality standards.
Zalgen Labs is at the forefront of hemorrhagic fever research, developing diagnostics, therapeutics, and vaccines for viral diseases such as Lassa fever and Ebola. Their rapid diagnostic tests are widely used in outbreak settings, and their antibody therapies show promise in treating severe viral infections. As one of the critical Rockville biotech companies engaged in global health security, Zalgen Labs plays a significant role in infectious disease preparedness.
Novavax is a vaccine development company known for its protein-based COVID-19 vaccine, Nuvaxovid. Their recombinant nanoparticle vaccine platform is also being applied to develop vaccines for influenza, RSV, and other emerging infectious diseases. With a focus on global vaccine accessibility, Novavax remains a major contributor to Rockville MD pharmaceutical companies working on infectious disease prevention.
Altimmune is a clinical-stage biopharmaceutical company developing intranasal vaccines and immunotherapies. Their lead candidates include AdCOVID, an intranasal COVID-19 vaccine, and HepTcell, an immunotherapy for chronic hepatitis B. Their novel drug delivery approaches position them among innovative biotech companies Rockville MD advancing immune-based treatments.
Supernus Pharmaceuticals develops treatments for central nervous system (CNS) disorders, including epilepsy, ADHD, and Parkinson’s disease. Their portfolio includes FDA-approved products such as Qelbree for ADHD and Gocovri for Parkinson’s disease. The company’s continuous innovation in neurology places them at the forefront of Rockville pharmaceutical companies improving mental health and neurological care.
Sanaria is dedicated to developing a malaria vaccine using whole sporozoite technology. Their PfSPZ vaccine is undergoing clinical trials in multiple countries, including Africa and Southeast Asia, with promising results in malaria prevention. Their work in global health makes them one of the most impactful biotechnology companies in Rockville MD working to eradicate malaria.
Noble Life Sciences is a preclinical contract research organization (CRO) providing services in oncology, infectious diseases, and toxicology. The company specializes in in vivo efficacy testing, cell-based assays, and preclinical development support for biopharmaceutical companies. Their expertise in preclinical drug testing positions them as a key player among biotechnology companies in Rockville MD supporting translational research and clinical pipeline acceleration.
Conclusion
Rockville, Maryland, continues to be a powerhouse for biotechnology innovation, home to a diverse ecosystem of companies tackling some of the world's most pressing health challenges. From gene therapy pioneers like REGENXBIO to vaccine developers like Novavax and Sanaria, the city’s biotech sector is driving advances in immunotherapy, molecular diagnostics, precision medicine, and more. These biotech companies in Rockville MD are not only pushing the boundaries of science but also contributing to economic growth, job creation, and global health solutions.
As the industry evolves, companies in Rockville must continue to adapt by integrating automation, streamlining R&D workflows, and ensuring compliance with ever-changing regulations. For biotech firms looking to scale efficiently while maintaining data integrity, adopting digital tools and connected lab ecosystems is essential.
.jpg)
